Induced abortion is still a major health problem in the world and the most frequently
performed intervention in obstetrics and gynecology with an estimated total of 46 million …

The pattern and amount of blood loss following induction of therapeutic abortion using
mifepristone (RU 486) and a prostaglandin E analogue (gemeprost) was studied in 222 …

In September 2000, the Food and Drug Administration (FDA) approved mifepristone (also
known by the trade name Mifeprex or its original French name, RU-486) for use along with a …

Medical abortion offers an important alternative to surgical abortion for women with early
pregnancies who wish to avoid a surgical procedure. More than 3 million women worldwide …

Alternatives to regimens with mifepristone and a prostaglandin analog for medical abortion
emerged because of the need for accessible, effective, and safe options in areas of the …

Although it has been demonstrated that a combination of mifepristone and a prostaglandin is
an effective method of inducing abortion in early pregnancy, the optimum dose of the …

The antiprogesterone mifepristone in combination with a suitable prostaglandin provides an
effective method for induction of abortion in early pregnancy up to 63 days of gestation. The …

Medication abortion (also commonly referred to as medi cal abortion) is arguably the most
important advance in reproductive health technology since the discovery of oral …

Mifepristone is an orally active progesterone antagonist. It can be used for both
contraceptive and non-contraceptive clinical indications. It is a very effective drug for …

Medically induced abortion using a new regimen of oral mifepristone 600 mg and vaginal
misoprostol 800 μg (PGE1 analogue) was carried out in 100 women. Abortion occurred in all …